Cover Image

The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention...

Full description

Saved in:
Bibliographic Details
Main Authors: Schulman, Gerald (Author) , Berl, Tomas (Author) , Beck, Gerald J. (Author) , Remuzzi, Giuseppe (Author) , Ritz, Eberhard (Author) , Shimizu, Miho (Author) , Shobu, Yuko (Author) , Kikuchi, Mami (Author)
Format: Article (Journal)
Language:English
Published: 30 September 2016
In: BMC nephrology
Year: 2016, Volume: 17, Pages: 1-8
ISSN:1471-2369
DOI:10.1186/s12882-016-0357-9
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12882-016-0357-9
Verlag, lizenzpflichtig, Volltext: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-016-0357-9
Get full text
Author Notes:Gerald Schulman, Tomas Berl, Gerald J. Beck, Giuseppe Remuzzi, Eberhard Ritz, Miho Shimizu, Yuko Shobu and Mami Kikuchi
Description
Summary:The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational, randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention of Progression in Chronic Kidney Disease [EPPIC] trials) examined AST-120’s efficacy in slowing CKD progression. This study assessed the efficacy of AST-120 in the subgroup of patients from the United States of America (USA) in the EPPIC trials.
Item Description:Gesehen am 26.05.2020
Physical Description:Online Resource
ISSN:1471-2369
DOI:10.1186/s12882-016-0357-9

Similar Items